How Navana Pharma made profit even in crisis | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Tuesday
November 28, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
TUESDAY, NOVEMBER 28, 2023
How Navana Pharma made profit even in crisis

Economy

TBS Report
18 October, 2022, 10:50 pm
Last modified: 18 October, 2022, 10:56 pm

Related News

  • Navana Pharma allowed to issue Tk150cr bond
  • Navana Pharma posts record revenue, profit amid higher costs
  • Navana Pharma to convert 60% of Tk150cr bond into shares
  • Navana Pharma to renovate plant instead of setting up new one
  • Navana Pharma to issue Tk150cr bond for loan repayment

How Navana Pharma made profit even in crisis

TBS Report
18 October, 2022, 10:50 pm
Last modified: 18 October, 2022, 10:56 pm
Infographic: TBS
Infographic: TBS

Navana Pharmaceuticals Limited – which made its stock market debut yesterday under the 'N' category – has registered a handsome year-on-year growth in its business for the first nine months of fiscal 2021-22, thanks to massive sales in both local and foreign markets. 

The drug maker's profit increased by 45% to Tk19.18 crore, compared to the same period of FY21.

In the July to March period of FY22, its revenue stood at Tk366.22 crore, which was not only greater than that in the same nine months of the previous year but also higher than the annual revenue of FY21. The revenue in FY21 was Tk360.65 crore.

However, EBL Securities pointed out in its initial public offering (IPO) note about Navana Pharma that the company's profit margin for the nine-month period is lower than the industry average.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The note also reads that Navana Pharma's short-term loans increased by around 144%, pushing its financial expenses up by 158%.

EBL Securities further said that the drug maker's board of directors lacks diversity as it comprises mostly members from one family. Hence, any family dispute or conflict of interest can directly induce adversities in the company's future.

Earlier, the Bangladesh Securities and Exchange Commission (BSEC) allowed Navana Pharma to raise Tk75 crore through an IPO.

Its cut-off price was fixed at Tk34 per share through the electronic subscription system.

Qualified and institutional investors including mutual funds got 25% of shares at the cut-off price, whereas individual investors got the remaining shares at Tk23.8 each – a 30% discount on the cut-off price.

Incorporated in 1986, Navana Pharma operates in two categories of pharmaceuticals: veterinary and human health.

The veterinary division manufactures and markets more than 123 high-quality medicines and feed supplements that include poultry, dairy, and aqua products.

While the human health division produces more than 277 drugs as tablets, capsules, oral liquids, ampoules, dry powder vials, powders for suspension, eye drops, creams and ointments, and more.

Top News

Navana Pharma

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image
    National Housing allowed to issue Tk374cr bond
  • Senior secretary Dr Ahmed Munirus Salehin Expatriates' Welfare and Overseas Employment Ministry made the disclosure while speaking at a meeting at Probashi Kallyan Bhaban on Tuesday (28 November). Photo: UNB
    Govt to provide Tk 270cr incentive to 2 lakh overseas returnees
  • File photo of Election Commissioner Rashida Sultana at her Agargaon office in the capital
    MPs must resign before contesting as independent candidates? EC Rashida statement raises confusion 

MOST VIEWED

  • JS polls: Full list of AL nominations
    JS polls: Full list of AL nominations
  •  File photo of a North Korean flag. REUTERS
    North Korea shuts down its embassy in Bangladesh
  • BSEC asks Bank Asia to explain 'vanished' investment in UFS
    BSEC asks Bank Asia to explain 'vanished' investment in UFS
  • TBS Infographics
    Thermax defaults on dollar loans under export fund: Cenbank
  • Chairman of the Minimum Wage Board Liaquat Ali Molla at a press conference in the Secretariat after the board’s 7th meeting today (26 November). Photo: TBS
    Tk12,500 minimum wage finalised for RMG, calls for increases unheeded 
  • Tax return time extension likely
    Tax return time extension likely

Related News

  • Navana Pharma allowed to issue Tk150cr bond
  • Navana Pharma posts record revenue, profit amid higher costs
  • Navana Pharma to convert 60% of Tk150cr bond into shares
  • Navana Pharma to renovate plant instead of setting up new one
  • Navana Pharma to issue Tk150cr bond for loan repayment

Features

A lesson on living the moment: 20 years of Kal Ho Naa Ho

A lesson on living the moment: 20 years of Kal Ho Naa Ho

5h | Features
In Barishal’s case, the low-cost of travel via waterways encourages people to migrate to Dhaka and other cities, like Chattogram. Photo: Syed Zakir Hossain

Why nearly a-fifth of people from Barishal moved to Dhaka

5h | Panorama
Photo: Salahuddin Ahmed/TBS

Political unrest hampers admission prep for HSC 2023 intake

7h | Education
The architectural design of Anukrom is a triumph of purpose and ingenuity – a rectangular structure that stretches east to west, crafting out two courtyards. Photo: Shakil Hai

Anukrom: A mother’s dream, a son’s guilt and an award-winning home

7h | Habitat

More Videos from TBS

Pakistan may lose its opportunity to host the Champions Trophy in 2025

Pakistan may lose its opportunity to host the Champions Trophy in 2025

13m | TBS SPORTS
NZ to scrap ‘generational smoking ban’

NZ to scrap ‘generational smoking ban’

2h | TBS World
Musk in Israel to get back advertising!

Musk in Israel to get back advertising!

4h | TBS World
Businessmen who were nominated for various seats from AL

Businessmen who were nominated for various seats from AL

5h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net